vs

Side-by-side financial comparison of GREENPOWER MOTOR Co INC. (GP) and Xilio Therapeutics, Inc. (XLO). Click either name above to swap in a different company.

Xilio Therapeutics, Inc. is the larger business by last-quarter revenue ($13.7M vs $7.2M, roughly 1.9× GREENPOWER MOTOR Co INC.). Xilio Therapeutics, Inc. runs the higher net margin — 75.7% vs -65.6%, a 141.3% gap on every dollar of revenue.

GreenPower Motor Company Inc. is a Canadian electric bus manufacturer and distributor in North America. The company fabricates multiple zero-emission models, including transit buses, school buses, and double decker buses. GreenPower headquarters are in Vancouver, British Columbia, with a sales office in Rancho Cucamonga, California; an assembly facility in Porterville, California; and a production facility in South Charleston, West Virginia. Its stock is traded on Nasdaq the United States.

Xilio Therapeutics is a clinical-stage biotechnology company dedicated to developing novel tumor-selective immunotherapies for cancer treatment. Its product pipeline features candidates engineered to trigger anti-tumor immune responses specifically inside tumor microenvironments, reducing systemic toxicities, and it primarily targets oncology patient populations in North America and other global markets.

GP vs XLO — Head-to-Head

Bigger by revenue
XLO
XLO
1.9× larger
XLO
$13.7M
$7.2M
GP
Higher net margin
XLO
XLO
141.3% more per $
XLO
75.7%
-65.6%
GP

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
GP
GP
XLO
XLO
Revenue
$7.2M
$13.7M
Net Profit
$-4.7M
$10.4M
Gross Margin
14.6%
Operating Margin
-86.5%
Net Margin
-65.6%
75.7%
Revenue YoY
-11.5%
Net Profit YoY
-2.1%
179.1%
EPS (diluted)
$-0.17
$-3.74

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GP
GP
XLO
XLO
Q4 25
$13.7M
Q3 25
$19.1M
Q2 25
$8.1M
Q1 25
$2.9M
Q4 24
$7.2M
Q3 24
$5.3M
Q2 24
$3.0M
Q4 23
$8.2M
Net Profit
GP
GP
XLO
XLO
Q4 25
$10.4M
Q3 25
$-16.3M
Q2 25
$-15.8M
Q1 25
$-13.3M
Q4 24
$-4.7M
Q3 24
$-4.7M
Q2 24
$-5.4M
Q4 23
$-4.6M
Gross Margin
GP
GP
XLO
XLO
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
14.6%
Q3 24
8.6%
Q2 24
7.4%
Q4 23
16.6%
Operating Margin
GP
GP
XLO
XLO
Q4 25
-86.5%
Q3 25
-10.1%
Q2 25
-177.7%
Q1 25
-472.7%
Q4 24
Q3 24
Q2 24
Q4 23
Net Margin
GP
GP
XLO
XLO
Q4 25
75.7%
Q3 25
-85.4%
Q2 25
-196.0%
Q1 25
-452.7%
Q4 24
-65.6%
Q3 24
-87.9%
Q2 24
-179.8%
Q4 23
-56.9%
EPS (diluted)
GP
GP
XLO
XLO
Q4 25
$-3.74
Q3 25
$-0.11
Q2 25
$-0.16
Q1 25
$-0.18
Q4 24
$-0.17
Q3 24
$-0.18
Q2 24
$-0.21
Q4 23
$-0.19

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GP
GP
XLO
XLO
Cash + ST InvestmentsLiquidity on hand
$621.1K
$137.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$2.1M
$35.3M
Total Assets
$37.4M
$154.7M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GP
GP
XLO
XLO
Q4 25
$137.5M
Q3 25
$103.8M
Q2 25
$121.6M
Q1 25
$89.1M
Q4 24
$621.1K
Q3 24
$116.9K
Q2 24
$528.3K
Q4 23
$4.0M
Stockholders' Equity
GP
GP
XLO
XLO
Q4 25
$35.3M
Q3 25
$-8.1M
Q2 25
$7.1M
Q1 25
$10.7M
Q4 24
$2.1M
Q3 24
$4.2M
Q2 24
$8.6M
Q4 23
$18.1M
Total Assets
GP
GP
XLO
XLO
Q4 25
$154.7M
Q3 25
$133.7M
Q2 25
$133.8M
Q1 25
$103.7M
Q4 24
$37.4M
Q3 24
$39.4M
Q2 24
$43.5M
Q4 23
$50.2M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GP
GP
XLO
XLO
Operating Cash FlowLast quarter
$-1.1M
$-2.0M
Free Cash FlowOCF − Capex
$-2.1M
FCF MarginFCF / Revenue
-15.3%
Capex IntensityCapex / Revenue
0.7%
Cash ConversionOCF / Net Profit
-0.19×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GP
GP
XLO
XLO
Q4 25
$-2.0M
Q3 25
$-17.5M
Q2 25
$-14.5M
Q1 25
$29.0M
Q4 24
$-1.1M
Q3 24
$-1.3M
Q2 24
$-3.2M
Q4 23
$1.4M
Free Cash Flow
GP
GP
XLO
XLO
Q4 25
$-2.1M
Q3 25
Q2 25
$-14.9M
Q1 25
$29.0M
Q4 24
Q3 24
Q2 24
Q4 23
FCF Margin
GP
GP
XLO
XLO
Q4 25
-15.3%
Q3 25
Q2 25
-184.0%
Q1 25
988.3%
Q4 24
Q3 24
Q2 24
Q4 23
Capex Intensity
GP
GP
XLO
XLO
Q4 25
0.7%
Q3 25
0.0%
Q2 25
5.0%
Q1 25
0.8%
Q4 24
Q3 24
Q2 24
Q4 23
Cash Conversion
GP
GP
XLO
XLO
Q4 25
-0.19×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q4 23

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons